Download PDF

1. Company Snapshot

1.a. Company Description

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies.It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer.The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors.


Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza.The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection.The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Show Full description

1.b. Last Insights on SABS

SAB Biotherapeutics' recent performance was driven by several positive developments. The company raised $175 million in an oversubscribed private placement, which included strategic investor Sanofi, extending its operational runway until mid-2028. SAB BIO also achieved alignment with the FDA on its Phase 2b SAFEGUARD study for SAB-142, a potential treatment for type 1 diabetes. Additionally, the company will present at the European Association for the Study of Diabetes meeting, highlighting its progress. A recent comparison with Kalaris Therapeutics also highlighted SAB's strengths.

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

SAB BIO Reports Third Quarter Financial Results and Recent Business Highlights

Nov -13

Source: globenewswire.com

Card image cap

SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142

Nov -04

Source: globenewswire.com

Card image cap

SAB BIO to Participate in Upcoming Investor Conferences

Nov -04

Source: globenewswire.com

Card image cap

SAB Biotherapeutics (SABS) to Release Earnings on Wednesday

Nov -04

Source: defenseworld.net

Card image cap

Reviewing SAB Biotherapeutics (NASDAQ:SABS) and Kalaris Therapeutics (NASDAQ:KLRS)

Oct -24

Source: defenseworld.net

Card image cap

SAB BIO Highlights Data in Multiple Presentations at EASD

Sep -19

Source: globenewswire.com

Card image cap

SAB BIO to Deliver Five Presentations Related to SAB-142 at the 2025 Annual Meeting of the European Association for the Study of Diabetes

Sep -03

Source: globenewswire.com

Card image cap

SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Aug -07

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (11.30%)

6. Segments

Immunotheraphies

Expected Growth: 11.3%

SAB Biotherapeutics' immunotherapies growth is driven by increasing demand for cancer treatments, advancements in gene editing technologies, and strategic partnerships. The company's proprietary DiversitAb platform enables rapid development of targeted therapies, while its strong pipeline and collaborations with pharma companies fuel growth. Additionally, growing investments in immunotherapy research and development, as well as expanding indications for existing treatments, contribute to the 11.3% growth rate.

7. Detailed Products

DiversitAb

A novel, fully human polyclonal antibody therapeutic platform that leverages the natural diversity of the human immune system to develop targeted therapies for various diseases.

SAB-185

A fully human polyclonal antibody therapeutic candidate for the treatment of COVID-19

SAB-RBD

A novel, fully human polyclonal antibody therapeutic candidate for the treatment of COVID-19 and other coronaviruses

SAB-155

A fully human polyclonal antibody therapeutic candidate for the treatment of seasonal influenza

SAB-195

A fully human polyclonal antibody therapeutic candidate for the treatment of Clostridiium difficile infection (CDI)

8. SAB Biotherapeutics, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

SAB Biotherapeutics, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies for diseases.

Bargaining Power Of Customers

The bargaining power of customers is low due to the specialized nature of SAB Biotherapeutics, Inc.'s products and the lack of alternatives.

Bargaining Power Of Suppliers

The bargaining power of suppliers is moderate due to the presence of multiple suppliers for raw materials and the company's dependence on a few key suppliers.

Threat Of New Entrants

The threat of new entrants is low due to the high barriers to entry in the biotechnology industry, including the need for significant capital investment and specialized expertise.

Intensity Of Rivalry

The intensity of rivalry is high due to the presence of several established players in the biotechnology industry, leading to intense competition for market share and talent.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 9.35%
Debt Cost 3.95%
Equity Weight 90.65%
Equity Cost 7.85%
WACC 7.48%
Leverage 10.31%

11. Quality Control: SAB Biotherapeutics, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Fennec Pharmaceuticals

A-Score: 6.0/10

Value: 8.2

Growth: 8.6

Quality: 6.4

Yield: 0.0

Momentum: 10.0

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Sage Therapeutics

A-Score: 4.9/10

Value: 7.4

Growth: 6.1

Quality: 4.8

Yield: 0.0

Momentum: 9.0

Volatility: 2.3

1-Year Total Return ->

View Full Report
Stock-Card
Synlogic

A-Score: 4.8/10

Value: 7.2

Growth: 5.6

Quality: 4.8

Yield: 0.0

Momentum: 8.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Bluebird Bio

A-Score: 3.6/10

Value: 9.8

Growth: 3.6

Quality: 5.1

Yield: 0.0

Momentum: 0.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
SAB Biotherapeutics

A-Score: 3.1/10

Value: 8.8

Growth: 1.2

Quality: 6.9

Yield: 0.0

Momentum: 1.5

Volatility: 0.3

1-Year Total Return ->

View Full Report
Stock-Card
Enanta Pharmaceuticals

A-Score: 2.8/10

Value: 7.2

Growth: 1.2

Quality: 3.9

Yield: 0.0

Momentum: 4.0

Volatility: 0.3

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.98$

Current Price

3.98$

Potential

-0.00%

Expected Cash-Flows